NASDAQ: ERNAErnexa Therapeutics Inc Stock
$1.29-0.09 (-6.52%)
Updated Sep 12, 2025
ERNA Price
$1.29
Fair Value Price
$0.04
Market Cap
$9.90M
52 Week Low
$1.19
52 Week High
$22.80
P/E
-0.07x
P/B
2.23x
P/S
19.53x
PEG
N/A
Dividend Yield
N/A
Revenue
$488.00k
Earnings
-$43.70M
Gross Margin
112.3%
Operating Margin
-7,890.57%
Profit Margin
-8,959%
Debt to Equity
0.71
Operating Cash Flow
-$14M
Beta
1.19
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ERNA Overview
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ERNA's potential to beat the market
- ERNA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ERNA
RankedUnranked of 476
RankedUnranked of 476
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.30 | A | |
| $37.96 | A | |
| $7.91 | A |
Be the first to know about important ERNA news, forecast changes, insider trades & much more!
ERNA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ERNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ERNA ($1.29) is overvalued by 3,278.56% relative to our estimate of its Fair Value price of $0.04 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ERNA ($1.29) is not significantly undervalued (3,278.56%) relative to our estimate of its Fair Value price of $0.04 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ERNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ERNA due diligence checks available for Premium users.
Valuation
ERNA fair value
Fair Value of ERNA stock based on Discounted Cash Flow (DCF)
Price
$1.29
Fair Value
$0.04
Overvalued by
3,278.56%
ERNA ($1.29) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ERNA ($1.29) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ERNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ERNA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.07x
Industry
-97.08x
Market
36.98x
ERNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.23x
Industry
4.65x
ERNA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ERNA's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.1M
Profit Margin
0%
ERNA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ERNA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$7.6M
Liabilities
$3.1M
Debt to equity
0.71
ERNA's short-term assets ($4.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ERNA's short-term assets ($4.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ERNA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ERNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.5M
Investing
$0.0
Financing
$4.9M
ERNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ERNA vs Biotech Stocks
Ernexa Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.